AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
AstraZeneca(AZN) stock is priced at $178.75, giving the company a market capitalization of 277.23B. It carries a P/E multiple of 27.20 and pays a dividend yield of 1.7%.
On 2026-06-12, AstraZeneca(AZN) stock traded between a low of $178.59 and a high of $182.69. Shares are currently priced at $178.75, which is +0.1% above the low and -2.2% below the high.
AstraZeneca(AZN) shares are trading with a volume of 2.39M, against a daily average of 2.2M.
In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.
In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.
AZN News
AstraZeneca (AZN) on Friday announced that the U.S. Food and Drug Administration approved a label expansion for its anti-tumor agent Truqap (capivasertib) as pa...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is preparing a new early-stage trial that looks at how its drug AZD13...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The GRANITE study, formally titled “Airsupra Effectiveness in the Real World,” reviews...
Analyst ratings
83%
of 29 ratingsMore AZN News
Astrazeneca (AZN) ended the recent trading session at $75.57, demonstrating a +1.79% swing from the preceding day's closing price. This change outpaced the S&P...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca has launched a new mid‑stage study in heart disease tied to transthyr...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) is running a new early-stage obesity study titled “A Phase...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The study, officially titled “A Phase I, Randomized, Single-dose, 3-Period, Open-...
Analyst James Quigley of Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of p16,525.00. James Quigley has given his Buy rating due to...
Kyntra Bio ( (KYNB) ) just unveiled an update. On August 29, 2025, Kyntra Bio closed the sale of its China operations, held through FibroGen International (Hon...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca Tests New Drug Combo In Early Study The study called “An Open-label...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.